- Previous Close
100.15 - Open
99.58 - Bid 99.72 x --
- Ask 99.76 x --
- Day's Range
99.10 - 100.25 - 52 Week Range
82.72 - 112.35 - Volume
52,967 - Avg. Volume
107,360 - Market Cap (intraday)
5.34B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
29.31 - EPS (TTM)
3.41 - Earnings Date Mar 13, 2025 - Mar 17, 2025
- Forward Dividend & Yield 1.15 (1.15%)
- Ex-Dividend Date May 20, 2024
- 1y Target Est
106.89
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.
int.diasorin.com3,184
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DIA.MI
View MorePerformance Overview: DIA.MI
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DIA.MI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DIA.MI
View MoreValuation Measures
Market Cap
5.33B
Enterprise Value
6.14B
Trailing P/E
29.28
Forward P/E
21.60
PEG Ratio (5yr expected)
1.41
Price/Sales (ttm)
4.52
Price/Book (mrq)
3.30
Enterprise Value/Revenue
5.21
Enterprise Value/EBITDA
24.31
Financial Highlights
Profitability and Income Statement
Profit Margin
16.03%
Return on Assets (ttm)
5.73%
Return on Equity (ttm)
11.85%
Revenue (ttm)
1.18B
Net Income Avi to Common (ttm)
188.85M
Diluted EPS (ttm)
3.41
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
42.61%
Levered Free Cash Flow (ttm)
--